| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Thrombocytopenia | 14 | 2013 | 122 | 1.410 |
Why?
|
| Biomarkers, Tumor | 4 | 2012 | 508 | 1.140 |
Why?
|
| Copper | 3 | 2014 | 149 | 1.110 |
Why?
|
| Heparin | 5 | 2016 | 205 | 1.110 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 5 | 2011 | 47 | 0.970 |
Why?
|
| Pancytopenia | 3 | 2014 | 10 | 0.930 |
Why?
|
| Factor VIII | 13 | 2006 | 27 | 0.900 |
Why?
|
| Bone Marrow Transplantation | 4 | 2014 | 149 | 0.890 |
Why?
|
| Thrombosis | 7 | 2017 | 218 | 0.890 |
Why?
|
| Skin Neoplasms | 3 | 2016 | 375 | 0.850 |
Why?
|
| Multiple Myeloma | 3 | 2018 | 92 | 0.790 |
Why?
|
| Lymphoma | 4 | 2010 | 116 | 0.790 |
Why?
|
| Blood Platelets | 18 | 1996 | 284 | 0.780 |
Why?
|
| Mastocytosis | 2 | 2016 | 6 | 0.770 |
Why?
|
| Humans | 123 | 2019 | 68525 | 0.760 |
Why?
|
| Liver Transplantation | 5 | 2011 | 400 | 0.750 |
Why?
|
| von Willebrand Disease, Type 3 | 1 | 2019 | 2 | 0.700 |
Why?
|
| Bone Marrow | 6 | 2018 | 168 | 0.690 |
Why?
|
| Partial Thromboplastin Time | 11 | 2008 | 57 | 0.680 |
Why?
|
| Diagnosis, Differential | 13 | 2017 | 1139 | 0.650 |
Why?
|
| Immunoglobulin G | 8 | 2015 | 481 | 0.630 |
Why?
|
| Leukemia, Plasma Cell | 1 | 2017 | 6 | 0.630 |
Why?
|
| Female | 68 | 2019 | 38015 | 0.620 |
Why?
|
| Anticoagulants | 4 | 2008 | 356 | 0.610 |
Why?
|
| Factor V | 6 | 2008 | 20 | 0.600 |
Why?
|
| Lymphoma, B-Cell | 2 | 2016 | 40 | 0.600 |
Why?
|
| Male | 63 | 2019 | 37281 | 0.590 |
Why?
|
| Killer Cells, Natural | 2 | 2007 | 94 | 0.550 |
Why?
|
| Blood Coagulation Disorders | 6 | 2004 | 45 | 0.530 |
Why?
|
| Hodgkin Disease | 3 | 2011 | 27 | 0.530 |
Why?
|
| Granuloma, Plasma Cell | 1 | 2015 | 8 | 0.520 |
Why?
|
| Adult | 44 | 2018 | 21375 | 0.510 |
Why?
|
| Lymphoma, T-Cell, Cutaneous | 1 | 2014 | 10 | 0.510 |
Why?
|
| Bone Neoplasms | 2 | 2014 | 100 | 0.500 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2014 | 79 | 0.480 |
Why?
|
| Middle Aged | 38 | 2018 | 21119 | 0.470 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2014 | 151 | 0.460 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 3 | 2018 | 50 | 0.460 |
Why?
|
| Platelet Factor 4 | 1 | 2013 | 10 | 0.450 |
Why?
|
| Testicular Neoplasms | 2 | 2010 | 27 | 0.450 |
Why?
|
| Lymphoma, AIDS-Related | 2 | 2010 | 5 | 0.440 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2014 | 234 | 0.430 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2012 | 13 | 0.430 |
Why?
|
| Gingival Neoplasms | 1 | 2011 | 13 | 0.420 |
Why?
|
| Neutropenia | 2 | 2012 | 72 | 0.410 |
Why?
|
| Flow Cytometry | 11 | 2009 | 489 | 0.410 |
Why?
|
| Neuroblastoma | 1 | 2013 | 109 | 0.410 |
Why?
|
| Antigens, CD20 | 2 | 2011 | 6 | 0.410 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2011 | 144 | 0.400 |
Why?
|
| Adolescent | 20 | 2018 | 8903 | 0.400 |
Why?
|
| Platelet Count | 12 | 2013 | 100 | 0.400 |
Why?
|
| Fatal Outcome | 6 | 2014 | 164 | 0.400 |
Why?
|
| Anemia | 2 | 2012 | 104 | 0.400 |
Why?
|
| Intensive Care Units | 2 | 2013 | 344 | 0.390 |
Why?
|
| Infant | 11 | 2018 | 2891 | 0.390 |
Why?
|
| Venous Thrombosis | 3 | 2018 | 124 | 0.390 |
Why?
|
| Kidney Transplantation | 4 | 2005 | 839 | 0.380 |
Why?
|
| PAX5 Transcription Factor | 1 | 2010 | 9 | 0.380 |
Why?
|
| Autoantibodies | 7 | 2006 | 434 | 0.380 |
Why?
|
| Myeloproliferative Disorders | 1 | 2010 | 11 | 0.380 |
Why?
|
| Translocation, Genetic | 1 | 2010 | 74 | 0.370 |
Why?
|
| Child, Preschool | 13 | 2019 | 3185 | 0.360 |
Why?
|
| Chromosomes, Human, Pair 8 | 2 | 2010 | 54 | 0.360 |
Why?
|
| Sarcoma, Myeloid | 2 | 2009 | 11 | 0.360 |
Why?
|
| Graft vs Host Disease | 2 | 2011 | 163 | 0.350 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2010 | 121 | 0.350 |
Why?
|
| Mediastinal Neoplasms | 2 | 2006 | 27 | 0.340 |
Why?
|
| Neural Tube Defects | 1 | 2008 | 27 | 0.340 |
Why?
|
| Biopsy | 5 | 2015 | 539 | 0.330 |
Why?
|
| Gastroenteritis | 1 | 2008 | 19 | 0.320 |
Why?
|
| Budd-Chiari Syndrome | 1 | 2008 | 7 | 0.320 |
Why?
|
| von Willebrand Diseases | 5 | 1995 | 11 | 0.320 |
Why?
|
| Anemia, Hemolytic, Autoimmune | 1 | 2007 | 3 | 0.310 |
Why?
|
| Hemophilia A | 3 | 2006 | 9 | 0.310 |
Why?
|
| Immunoglobulins | 2 | 2017 | 97 | 0.310 |
Why?
|
| Leukemia-Lymphoma, Adult T-Cell | 1 | 2007 | 11 | 0.300 |
Why?
|
| von Willebrand Factor | 8 | 1995 | 47 | 0.300 |
Why?
|
| Leukemia, Promyelocytic, Acute | 2 | 2004 | 17 | 0.290 |
Why?
|
| Hemoglobins, Abnormal | 2 | 1999 | 5 | 0.290 |
Why?
|
| Heart Diseases | 2 | 2008 | 276 | 0.290 |
Why?
|
| Leukemia | 1 | 2007 | 117 | 0.290 |
Why?
|
| Ascites | 1 | 2006 | 38 | 0.290 |
Why?
|
| Cerebral Hemorrhage | 3 | 1994 | 198 | 0.290 |
Why?
|
| Isoantibodies | 6 | 1998 | 35 | 0.290 |
Why?
|
| Aged | 21 | 2018 | 14842 | 0.280 |
Why?
|
| Deamino Arginine Vasopressin | 2 | 1996 | 15 | 0.280 |
Why?
|
| Hydroxyethyl Starch Derivatives | 2 | 1996 | 24 | 0.280 |
Why?
|
| Myelolipoma | 1 | 2006 | 3 | 0.280 |
Why?
|
| Polysaccharides | 1 | 2008 | 176 | 0.280 |
Why?
|
| Granulocyte Precursor Cells | 2 | 2009 | 6 | 0.280 |
Why?
|
| Hypereosinophilic Syndrome | 1 | 2005 | 3 | 0.280 |
Why?
|
| Bone Marrow Cells | 3 | 2013 | 217 | 0.280 |
Why?
|
| Heterozygote | 2 | 2019 | 174 | 0.270 |
Why?
|
| Trisomy | 1 | 2005 | 47 | 0.270 |
Why?
|
| Leukemia, Monocytic, Acute | 1 | 2005 | 9 | 0.270 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2006 | 46 | 0.270 |
Why?
|
| Chediak-Higashi Syndrome | 1 | 2005 | 1 | 0.270 |
Why?
|
| Pulmonary Embolism | 3 | 2017 | 253 | 0.270 |
Why?
|
| Time | 1 | 2005 | 57 | 0.270 |
Why?
|
| DiGeorge Syndrome | 1 | 2005 | 13 | 0.260 |
Why?
|
| Cytodiagnosis | 1 | 2005 | 20 | 0.260 |
Why?
|
| Antibodies, Monoclonal | 3 | 2010 | 510 | 0.260 |
Why?
|
| Peptide Fragments | 1 | 2008 | 483 | 0.260 |
Why?
|
| Hypercalcemia | 2 | 2004 | 34 | 0.260 |
Why?
|
| Leukemia, Myeloid, Acute | 3 | 2009 | 116 | 0.260 |
Why?
|
| Cytomegalovirus | 1 | 2005 | 63 | 0.250 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2004 | 11 | 0.250 |
Why?
|
| Cytomegalovirus Infections | 1 | 2005 | 69 | 0.250 |
Why?
|
| Blood Coagulation Factors | 4 | 1989 | 44 | 0.250 |
Why?
|
| Blood Coagulation | 6 | 2008 | 123 | 0.250 |
Why?
|
| Kidney Neoplasms | 1 | 2006 | 206 | 0.250 |
Why?
|
| Pyrimidines | 1 | 2005 | 178 | 0.250 |
Why?
|
| Infant, Premature, Diseases | 3 | 2004 | 85 | 0.240 |
Why?
|
| Piperazines | 1 | 2005 | 206 | 0.240 |
Why?
|
| Maternal-Fetal Exchange | 3 | 1994 | 57 | 0.240 |
Why?
|
| Vitamin K | 2 | 1994 | 14 | 0.240 |
Why?
|
| Infant, Newborn | 12 | 2016 | 2453 | 0.230 |
Why?
|
| Heart Transplantation | 2 | 2008 | 328 | 0.230 |
Why?
|
| Immunophenotyping | 4 | 2007 | 110 | 0.230 |
Why?
|
| Thromboembolism | 2 | 2003 | 91 | 0.230 |
Why?
|
| Antigens | 10 | 1994 | 90 | 0.220 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 2 | 2013 | 9 | 0.210 |
Why?
|
| Lymphoma, Follicular | 1 | 2002 | 6 | 0.210 |
Why?
|
| Lymphoma, T-Cell | 1 | 2002 | 19 | 0.210 |
Why?
|
| Vimentin | 2 | 2012 | 47 | 0.210 |
Why?
|
| Extracellular Space | 1 | 2002 | 121 | 0.200 |
Why?
|
| Factor VIIa | 3 | 2011 | 25 | 0.200 |
Why?
|
| Postoperative Hemorrhage | 3 | 2011 | 69 | 0.200 |
Why?
|
| Hemorrhage | 2 | 2017 | 328 | 0.190 |
Why?
|
| Retrospective Studies | 9 | 2018 | 7264 | 0.190 |
Why?
|
| Blood Preservation | 3 | 1992 | 13 | 0.190 |
Why?
|
| Mutation | 3 | 2019 | 1213 | 0.190 |
Why?
|
| Pre-Eclampsia | 6 | 1987 | 202 | 0.180 |
Why?
|
| Renal Artery Obstruction | 1 | 2000 | 29 | 0.180 |
Why?
|
| Hemoglobin SC Disease | 1 | 1999 | 7 | 0.180 |
Why?
|
| alpha-Thalassemia | 1 | 1999 | 7 | 0.180 |
Why?
|
| Hemoglobin, Sickle | 1 | 1999 | 22 | 0.180 |
Why?
|
| Prospective Studies | 6 | 2018 | 3702 | 0.180 |
Why?
|
| Combined Modality Therapy | 4 | 2017 | 951 | 0.180 |
Why?
|
| Hematologic Tests | 1 | 1999 | 24 | 0.180 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 1 | 1999 | 6 | 0.180 |
Why?
|
| Young Adult | 9 | 2018 | 5708 | 0.180 |
Why?
|
| Recombinant Proteins | 5 | 2011 | 742 | 0.180 |
Why?
|
| Syndrome | 4 | 2016 | 255 | 0.170 |
Why?
|
| Leukemia, Myelomonocytic, Chronic | 1 | 1999 | 5 | 0.170 |
Why?
|
| Infant, Low Birth Weight | 3 | 1994 | 84 | 0.170 |
Why?
|
| Prognosis | 6 | 2013 | 2093 | 0.170 |
Why?
|
| Aged, 80 and over | 6 | 2018 | 4843 | 0.170 |
Why?
|
| Bone Marrow Diseases | 1 | 2018 | 3 | 0.170 |
Why?
|
| Immunoturbidimetry | 1 | 2018 | 1 | 0.170 |
Why?
|
| Lymphoproliferative Disorders | 2 | 2010 | 37 | 0.170 |
Why?
|
| Ikaros Transcription Factor | 1 | 2018 | 26 | 0.170 |
Why?
|
| Peptide Hydrolases | 1 | 2018 | 82 | 0.160 |
Why?
|
| Child | 12 | 2018 | 6400 | 0.160 |
Why?
|
| HLA-DR Antigens | 1 | 1998 | 41 | 0.160 |
Why?
|
| Pregnancy | 12 | 2013 | 2331 | 0.160 |
Why?
|
| Spleen | 1 | 1999 | 301 | 0.160 |
Why?
|
| Waldenstrom Macroglobulinemia | 1 | 2017 | 10 | 0.160 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2017 | 15 | 0.160 |
Why?
|
| Proto-Oncogene Proteins c-pim-1 | 1 | 2018 | 87 | 0.160 |
Why?
|
| Chromosome Deletion | 1 | 2017 | 41 | 0.160 |
Why?
|
| Babesiosis | 1 | 2017 | 9 | 0.150 |
Why?
|
| Transfusion Reaction | 1 | 2017 | 33 | 0.150 |
Why?
|
| Immunohistochemistry | 4 | 2010 | 1174 | 0.150 |
Why?
|
| Chromogranin A | 1 | 2016 | 2 | 0.150 |
Why?
|
| Angiography | 2 | 2017 | 194 | 0.150 |
Why?
|
| Prostaglandin D2 | 1 | 2016 | 21 | 0.150 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 3 | 2017 | 245 | 0.150 |
Why?
|
| Platelet Aggregation Inhibitors | 2 | 2017 | 373 | 0.150 |
Why?
|
| Prothrombin Time | 5 | 2003 | 24 | 0.150 |
Why?
|
| Renal Agents | 1 | 1996 | 8 | 0.150 |
Why?
|
| Plasma Substitutes | 1 | 1996 | 15 | 0.150 |
Why?
|
| Histamine | 1 | 2016 | 52 | 0.150 |
Why?
|
| Thrombin | 3 | 1998 | 117 | 0.150 |
Why?
|
| Immunoglobulin M | 1 | 2017 | 172 | 0.150 |
Why?
|
| Biological Assay | 1 | 2017 | 88 | 0.140 |
Why?
|
| Biomarkers | 3 | 2017 | 1593 | 0.140 |
Why?
|
| Myelodysplastic Syndromes | 2 | 2012 | 24 | 0.140 |
Why?
|
| Fibrinogen | 4 | 1996 | 87 | 0.140 |
Why?
|
| Immunosuppressive Agents | 3 | 2010 | 514 | 0.140 |
Why?
|
| Aspirin | 1 | 2017 | 295 | 0.140 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2018 | 331 | 0.140 |
Why?
|
| Antigen-Antibody Complex | 2 | 1986 | 175 | 0.130 |
Why?
|
| Platelet Aggregation | 3 | 1991 | 127 | 0.130 |
Why?
|
| Liver Neoplasms | 1 | 1999 | 334 | 0.130 |
Why?
|
| Polyps | 1 | 2015 | 12 | 0.130 |
Why?
|
| Skull Neoplasms | 1 | 2015 | 23 | 0.130 |
Why?
|
| Adalimumab | 1 | 2014 | 16 | 0.130 |
Why?
|
| Fibronectins | 4 | 1990 | 130 | 0.120 |
Why?
|
| Lupus Erythematosus, Systemic | 3 | 2013 | 756 | 0.120 |
Why?
|
| Immunoenzyme Techniques | 2 | 2012 | 196 | 0.120 |
Why?
|
| Heart-Assist Devices | 1 | 2017 | 221 | 0.120 |
Why?
|
| Sarcoma, Ewing | 1 | 2014 | 26 | 0.120 |
Why?
|
| Psoriasis | 1 | 2014 | 46 | 0.120 |
Why?
|
| Allografts | 1 | 2014 | 63 | 0.120 |
Why?
|
| Blood Grouping and Crossmatching | 2 | 1993 | 8 | 0.120 |
Why?
|
| Radiation-Protective Agents | 1 | 2013 | 16 | 0.120 |
Why?
|
| Thioredoxins | 1 | 2013 | 26 | 0.120 |
Why?
|
| Thrombopoietin | 1 | 2013 | 15 | 0.120 |
Why?
|
| Thrombotic Microangiopathies | 1 | 2013 | 8 | 0.110 |
Why?
|
| Leukemia, Prolymphocytic, T-Cell | 1 | 2013 | 3 | 0.110 |
Why?
|
| Hemorrhagic Disorders | 2 | 1998 | 7 | 0.110 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2013 | 507 | 0.110 |
Why?
|
| Hemoglobin C | 1 | 1992 | 3 | 0.110 |
Why?
|
| Treatment Outcome | 6 | 2017 | 7028 | 0.110 |
Why?
|
| Anemia, Sickle Cell | 3 | 2010 | 364 | 0.110 |
Why?
|
| Bone Marrow Examination | 2 | 2018 | 6 | 0.110 |
Why?
|
| Factor VII | 3 | 2004 | 8 | 0.110 |
Why?
|
| Fetomaternal Transfusion | 1 | 2012 | 1 | 0.110 |
Why?
|
| Chromogranins | 1 | 2012 | 4 | 0.110 |
Why?
|
| Plasma Exchange | 2 | 2013 | 18 | 0.110 |
Why?
|
| Acute Kidney Injury | 2 | 2013 | 232 | 0.110 |
Why?
|
| Synaptophysin | 1 | 2012 | 16 | 0.110 |
Why?
|
| Prenatal Care | 1 | 1993 | 117 | 0.110 |
Why?
|
| Cytoplasm | 2 | 2005 | 155 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-bcl-6 | 1 | 2011 | 4 | 0.110 |
Why?
|
| Mandibular Neoplasms | 1 | 2011 | 16 | 0.110 |
Why?
|
| Leukocyte Common Antigens | 1 | 2011 | 41 | 0.100 |
Why?
|
| Liver | 2 | 2008 | 1118 | 0.100 |
Why?
|
| Hematopoietic Stem Cells | 2 | 2013 | 268 | 0.100 |
Why?
|
| Neprilysin | 1 | 2011 | 55 | 0.100 |
Why?
|
| Sphingomyelin Phosphodiesterase | 1 | 2013 | 183 | 0.100 |
Why?
|
| Time Factors | 5 | 2014 | 4655 | 0.100 |
Why?
|
| Purpura, Thrombocytopenic | 1 | 1991 | 3 | 0.100 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2013 | 376 | 0.100 |
Why?
|
| HLA Antigens | 2 | 1990 | 82 | 0.100 |
Why?
|
| Noonan Syndrome | 1 | 1991 | 6 | 0.100 |
Why?
|
| Polymerase Chain Reaction | 2 | 2005 | 492 | 0.100 |
Why?
|
| Herpesvirus 4, Human | 2 | 2010 | 30 | 0.100 |
Why?
|
| Proteomics | 1 | 2013 | 246 | 0.100 |
Why?
|
| Hemostatic Techniques | 1 | 2011 | 23 | 0.100 |
Why?
|
| Chimerism | 1 | 2011 | 4 | 0.100 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 1991 | 73 | 0.100 |
Why?
|
| Neoplasm Metastasis | 1 | 2012 | 306 | 0.100 |
Why?
|
| Up-Regulation | 1 | 2013 | 682 | 0.100 |
Why?
|
| Hemostatics | 1 | 2011 | 47 | 0.100 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2013 | 1745 | 0.100 |
Why?
|
| Lymphoma, Large-Cell, Anaplastic | 1 | 2010 | 3 | 0.100 |
Why?
|
| Blood Coagulation Disorders, Inherited | 2 | 2008 | 5 | 0.100 |
Why?
|
| Emergency Service, Hospital | 1 | 2017 | 711 | 0.100 |
Why?
|
| Keratinocytes | 1 | 2011 | 68 | 0.100 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 2 | 2010 | 33 | 0.090 |
Why?
|
| Mandibular Diseases | 1 | 2010 | 28 | 0.090 |
Why?
|
| Drug Costs | 1 | 2011 | 87 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 2010 | 23 | 0.090 |
Why?
|
| Hepatitis, Autoimmune | 1 | 2010 | 22 | 0.090 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2010 | 24 | 0.090 |
Why?
|
| Neoplasm Invasiveness | 1 | 2011 | 369 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 2010 | 56 | 0.090 |
Why?
|
| Sphingolipids | 1 | 2013 | 337 | 0.090 |
Why?
|
| Hospital Costs | 1 | 2011 | 117 | 0.090 |
Why?
|
| Mycophenolic Acid | 1 | 2010 | 62 | 0.090 |
Why?
|
| Rituximab | 2 | 2010 | 61 | 0.090 |
Why?
|
| Nafcillin | 1 | 1990 | 3 | 0.090 |
Why?
|
| Hematoma, Epidural, Cranial | 1 | 1990 | 5 | 0.090 |
Why?
|
| Neoplasm Staging | 3 | 2008 | 799 | 0.090 |
Why?
|
| Antibodies | 3 | 1988 | 241 | 0.090 |
Why?
|
| Graft Survival | 2 | 2005 | 465 | 0.090 |
Why?
|
| Remission Induction | 2 | 2010 | 111 | 0.090 |
Why?
|
| Streptococcal Infections | 1 | 1990 | 53 | 0.090 |
Why?
|
| United States | 6 | 2018 | 7335 | 0.090 |
Why?
|
| Thrombasthenia | 1 | 2009 | 3 | 0.090 |
Why?
|
| Gene Expression Regulation, Leukemic | 1 | 2009 | 29 | 0.090 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2009 | 40 | 0.090 |
Why?
|
| Tricuspid Valve Insufficiency | 1 | 2009 | 25 | 0.090 |
Why?
|
| Heart Septal Defects, Ventricular | 1 | 2009 | 59 | 0.090 |
Why?
|
| Parenteral Nutrition, Total | 1 | 2008 | 22 | 0.080 |
Why?
|
| Cell Lineage | 1 | 2009 | 146 | 0.080 |
Why?
|
| Short Bowel Syndrome | 1 | 2008 | 15 | 0.080 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2009 | 124 | 0.080 |
Why?
|
| Treatment Failure | 2 | 2000 | 216 | 0.080 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2011 | 265 | 0.080 |
Why?
|
| Protein S Deficiency | 2 | 1999 | 4 | 0.080 |
Why?
|
| Critical Care | 1 | 2011 | 263 | 0.080 |
Why?
|
| Enterocolitis, Necrotizing | 1 | 2008 | 37 | 0.080 |
Why?
|
| Triiodobenzoic Acids | 1 | 2008 | 28 | 0.080 |
Why?
|
| Research Design | 1 | 2013 | 729 | 0.080 |
Why?
|
| Iopamidol | 1 | 2008 | 37 | 0.080 |
Why?
|
| Thrombocythemia, Essential | 1 | 1987 | 2 | 0.080 |
Why?
|
| Phosphoproteins | 1 | 2009 | 202 | 0.080 |
Why?
|
| Hirudins | 1 | 2008 | 32 | 0.080 |
Why?
|
| Immunoglobulin Fab Fragments | 2 | 1985 | 48 | 0.080 |
Why?
|
| Antithrombins | 1 | 2008 | 32 | 0.080 |
Why?
|
| Erythrocytes | 1 | 2008 | 137 | 0.080 |
Why?
|
| Iohexol | 1 | 2008 | 82 | 0.080 |
Why?
|
| Cryoglobulins | 1 | 2007 | 4 | 0.080 |
Why?
|
| Temperature | 2 | 2008 | 340 | 0.080 |
Why?
|
| DNA-Binding Proteins | 1 | 2011 | 700 | 0.080 |
Why?
|
| Skin | 1 | 2011 | 451 | 0.080 |
Why?
|
| Purpura, Thrombotic Thrombocytopenic | 1 | 1987 | 21 | 0.080 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2009 | 164 | 0.080 |
Why?
|
| Transcription Factors | 1 | 2011 | 753 | 0.080 |
Why?
|
| Reoperation | 3 | 2011 | 467 | 0.080 |
Why?
|
| RNA-Binding Proteins | 1 | 2009 | 215 | 0.080 |
Why?
|
| United States Food and Drug Administration | 2 | 2018 | 131 | 0.070 |
Why?
|
| Aortic Diseases | 1 | 2008 | 113 | 0.070 |
Why?
|
| Canada | 2 | 2018 | 266 | 0.070 |
Why?
|
| Outpatients | 2 | 2018 | 127 | 0.070 |
Why?
|
| Sepsis | 1 | 1990 | 233 | 0.070 |
Why?
|
| Afibrinogenemia | 1 | 1986 | 2 | 0.070 |
Why?
|
| Plicamycin | 1 | 1986 | 2 | 0.070 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2011 | 450 | 0.070 |
Why?
|
| Polycythemia Vera | 1 | 1986 | 2 | 0.070 |
Why?
|
| Hematopoiesis, Extramedullary | 1 | 2006 | 6 | 0.070 |
Why?
|
| Antibody Formation | 1 | 2006 | 93 | 0.070 |
Why?
|
| Cytogenetic Analysis | 1 | 2005 | 12 | 0.070 |
Why?
|
| Imatinib Mesylate | 1 | 2005 | 26 | 0.070 |
Why?
|
| Fluorescent Antibody Technique | 6 | 1990 | 282 | 0.070 |
Why?
|
| Granulocytes | 1 | 2005 | 22 | 0.070 |
Why?
|
| Aortic Valve Insufficiency | 1 | 2005 | 47 | 0.070 |
Why?
|
| Myeloid Progenitor Cells | 1 | 2005 | 9 | 0.070 |
Why?
|
| Eosinophils | 1 | 2005 | 60 | 0.070 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 1985 | 13 | 0.070 |
Why?
|
| Mitral Valve Insufficiency | 1 | 2005 | 99 | 0.060 |
Why?
|
| Follow-Up Studies | 1 | 2011 | 3256 | 0.060 |
Why?
|
| Histiocytosis, Non-Langerhans-Cell | 1 | 2004 | 5 | 0.060 |
Why?
|
| Fetal Blood | 4 | 1994 | 131 | 0.060 |
Why?
|
| DNA, Viral | 1 | 2005 | 114 | 0.060 |
Why?
|
| Platelet Transfusion | 3 | 2009 | 21 | 0.060 |
Why?
|
| Antigen-Antibody Reactions | 1 | 1984 | 13 | 0.060 |
Why?
|
| Gene Rearrangement, B-Lymphocyte, Heavy Chain | 1 | 2004 | 8 | 0.060 |
Why?
|
| Risk Factors | 5 | 2011 | 5719 | 0.060 |
Why?
|
| Cardiomegaly | 1 | 2005 | 213 | 0.060 |
Why?
|
| Benzamides | 1 | 2005 | 156 | 0.060 |
Why?
|
| Contrast Media | 1 | 2008 | 594 | 0.060 |
Why?
|
| Fibroblasts | 1 | 2009 | 902 | 0.060 |
Why?
|
| Antineoplastic Agents | 1 | 2012 | 1070 | 0.060 |
Why?
|
| Sensitivity and Specificity | 2 | 2018 | 1753 | 0.060 |
Why?
|
| Lupus Coagulation Inhibitor | 3 | 1989 | 15 | 0.060 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2013 | 2222 | 0.060 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2017 | 2323 | 0.060 |
Why?
|
| Prednisone | 3 | 2010 | 104 | 0.060 |
Why?
|
| Blood Loss, Surgical | 2 | 2009 | 79 | 0.060 |
Why?
|
| Europe | 2 | 2017 | 195 | 0.060 |
Why?
|
| Polycystic Kidney, Autosomal Dominant | 1 | 2003 | 25 | 0.060 |
Why?
|
| Receptors, Fc | 2 | 2013 | 19 | 0.050 |
Why?
|
| Periodic Acid-Schiff Reaction | 1 | 2002 | 6 | 0.050 |
Why?
|
| Eosine Yellowish-(YS) | 1 | 2002 | 6 | 0.050 |
Why?
|
| Hematoxylin | 1 | 2002 | 8 | 0.050 |
Why?
|
| Infant, Premature | 3 | 2004 | 284 | 0.050 |
Why?
|
| Molecular Biology | 1 | 2002 | 31 | 0.050 |
Why?
|
| Coloring Agents | 1 | 2002 | 66 | 0.050 |
Why?
|
| Predictive Value of Tests | 2 | 2000 | 1465 | 0.050 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 3 | 1990 | 272 | 0.050 |
Why?
|
| Animals | 8 | 2018 | 20877 | 0.050 |
Why?
|
| Double-Blind Method | 2 | 1996 | 1737 | 0.050 |
Why?
|
| Diabetes Complications | 1 | 2003 | 249 | 0.050 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2013 | 536 | 0.050 |
Why?
|
| Fluorescent Dyes | 1 | 2002 | 191 | 0.050 |
Why?
|
| Odds Ratio | 1 | 2003 | 880 | 0.050 |
Why?
|
| Mice | 4 | 2018 | 8472 | 0.050 |
Why?
|
| Pulmonary Artery | 1 | 2002 | 323 | 0.050 |
Why?
|
| Renal Veins | 1 | 2000 | 18 | 0.050 |
Why?
|
| Renal Artery | 1 | 2000 | 29 | 0.050 |
Why?
|
| Mesenteric Vascular Occlusion | 1 | 1999 | 20 | 0.050 |
Why?
|
| Blood Coagulation Tests | 3 | 2008 | 31 | 0.050 |
Why?
|
| Isoelectric Focusing | 1 | 1999 | 42 | 0.050 |
Why?
|
| Electrophoresis, Agar Gel | 1 | 1999 | 32 | 0.050 |
Why?
|
| Multivariate Analysis | 1 | 2003 | 1046 | 0.040 |
Why?
|
| Freezing | 3 | 1988 | 29 | 0.040 |
Why?
|
| Postoperative Care | 2 | 2011 | 163 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 2 | 2018 | 2790 | 0.040 |
Why?
|
| Homozygote | 1 | 1999 | 119 | 0.040 |
Why?
|
| Biopsy, Large-Core Needle | 1 | 2018 | 4 | 0.040 |
Why?
|
| Pyridazines | 1 | 2018 | 7 | 0.040 |
Why?
|
| Liver, Artificial | 1 | 1998 | 2 | 0.040 |
Why?
|
| Plasmapheresis | 1 | 1998 | 18 | 0.040 |
Why?
|
| Lung Neoplasms | 1 | 1988 | 1172 | 0.040 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 1999 | 381 | 0.040 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2018 | 69 | 0.040 |
Why?
|
| Protein Precursors | 1 | 1978 | 105 | 0.040 |
Why?
|
| Prevalence | 2 | 2017 | 1609 | 0.040 |
Why?
|
| Cell Nucleus | 1 | 1999 | 305 | 0.040 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2018 | 89 | 0.040 |
Why?
|
| Acute Disease | 1 | 2000 | 658 | 0.040 |
Why?
|
| Imidazoles | 1 | 2018 | 175 | 0.040 |
Why?
|
| Blood Donors | 1 | 2017 | 18 | 0.040 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2018 | 304 | 0.040 |
Why?
|
| Cytotoxicity Tests, Immunologic | 2 | 1987 | 22 | 0.040 |
Why?
|
| Renal Dialysis | 1 | 1998 | 174 | 0.040 |
Why?
|
| B-Lymphocytes | 1 | 1999 | 329 | 0.040 |
Why?
|
| Postoperative Complications | 1 | 2005 | 1615 | 0.040 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2018 | 214 | 0.040 |
Why?
|
| In Vitro Techniques | 2 | 1990 | 765 | 0.040 |
Why?
|
| Erythrocyte Transfusion | 1 | 2017 | 72 | 0.040 |
Why?
|
| Blood Transfusion | 2 | 1989 | 205 | 0.040 |
Why?
|
| Down-Regulation | 1 | 2018 | 447 | 0.040 |
Why?
|
| Fever | 1 | 2017 | 96 | 0.040 |
Why?
|
| Actins | 2 | 2009 | 249 | 0.040 |
Why?
|
| DNA | 1 | 1999 | 597 | 0.040 |
Why?
|
| Turner Syndrome | 1 | 1996 | 10 | 0.040 |
Why?
|
| Swine | 1 | 1998 | 672 | 0.040 |
Why?
|
| Osmolar Concentration | 2 | 2008 | 134 | 0.040 |
Why?
|
| Protein S | 1 | 1996 | 9 | 0.040 |
Why?
|
| Sodium Chloride | 1 | 1996 | 136 | 0.040 |
Why?
|
| Reference Values | 3 | 2008 | 579 | 0.040 |
Why?
|
| Fluid Therapy | 1 | 1996 | 59 | 0.040 |
Why?
|
| Intraoperative Care | 1 | 1996 | 91 | 0.040 |
Why?
|
| Elective Surgical Procedures | 1 | 1996 | 95 | 0.030 |
Why?
|
| Molecular Weight | 3 | 1993 | 358 | 0.030 |
Why?
|
| Severity of Illness Index | 2 | 2013 | 1851 | 0.030 |
Why?
|
| Nephrotic Syndrome | 1 | 1996 | 61 | 0.030 |
Why?
|
| Intraoperative Period | 1 | 1995 | 62 | 0.030 |
Why?
|
| Steroids | 1 | 1996 | 84 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 2 | 2017 | 1026 | 0.030 |
Why?
|
| Graft Rejection | 1 | 1998 | 458 | 0.030 |
Why?
|
| Cohort Studies | 2 | 2013 | 2356 | 0.030 |
Why?
|
| Analysis of Variance | 2 | 2010 | 1039 | 0.030 |
Why?
|
| Ristocetin | 1 | 1994 | 3 | 0.030 |
Why?
|
| Cells, Cultured | 3 | 2009 | 2673 | 0.030 |
Why?
|
| Blood Component Removal | 1 | 1994 | 19 | 0.030 |
Why?
|
| Protein C | 1 | 1994 | 4 | 0.030 |
Why?
|
| Prothrombin | 1 | 1994 | 12 | 0.030 |
Why?
|
| Chronic Disease | 3 | 1999 | 1329 | 0.030 |
Why?
|
| Injections, Intramuscular | 1 | 1994 | 44 | 0.030 |
Why?
|
| Stem Cell Niche | 1 | 2013 | 7 | 0.030 |
Why?
|
| Cellular Microenvironment | 1 | 2013 | 10 | 0.030 |
Why?
|
| Mice, Congenic | 1 | 2013 | 13 | 0.030 |
Why?
|
| Benzylamines | 1 | 2013 | 28 | 0.030 |
Why?
|
| Colony-Forming Units Assay | 1 | 2013 | 78 | 0.030 |
Why?
|
| Extracellular Fluid | 1 | 2013 | 29 | 0.030 |
Why?
|
| Heterocyclic Compounds | 1 | 2013 | 24 | 0.030 |
Why?
|
| Obstetric Labor, Premature | 1 | 1994 | 76 | 0.030 |
Why?
|
| Liver Abscess | 1 | 1973 | 9 | 0.030 |
Why?
|
| Streptokinase | 1 | 1993 | 23 | 0.030 |
Why?
|
| Hematopoiesis | 1 | 2013 | 108 | 0.030 |
Why?
|
| Empyema, Pleural | 1 | 1993 | 13 | 0.030 |
Why?
|
| Respiratory Distress Syndrome, Newborn | 1 | 1993 | 46 | 0.030 |
Why?
|
| Bronchopulmonary Dysplasia | 1 | 1993 | 34 | 0.030 |
Why?
|
| Rh Isoimmunization | 1 | 2012 | 6 | 0.030 |
Why?
|
| Rho(D) Immune Globulin | 1 | 2012 | 9 | 0.030 |
Why?
|
| Pregnancy Complications, Hematologic | 1 | 2012 | 15 | 0.030 |
Why?
|
| Mass Spectrometry | 1 | 2013 | 284 | 0.030 |
Why?
|
| Electrophoresis | 1 | 1992 | 69 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2018 | 2264 | 0.030 |
Why?
|
| Cryopreservation | 1 | 1992 | 103 | 0.030 |
Why?
|
| 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid | 1 | 1991 | 41 | 0.030 |
Why?
|
| Prostaglandin Endoperoxides, Synthetic | 1 | 1991 | 52 | 0.030 |
Why?
|
| Sphingosine | 1 | 2013 | 315 | 0.030 |
Why?
|
| Protein C Deficiency | 1 | 1991 | 5 | 0.020 |
Why?
|
| Adenosine Diphosphate | 1 | 1991 | 66 | 0.020 |
Why?
|
| Arachidonic Acids | 1 | 1991 | 97 | 0.020 |
Why?
|
| Lung Diseases | 1 | 1993 | 175 | 0.020 |
Why?
|
| Epinephrine | 1 | 1991 | 103 | 0.020 |
Why?
|
| Models, Economic | 1 | 2011 | 69 | 0.020 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2005 | 467 | 0.020 |
Why?
|
| Platelet Membrane Glycoproteins | 1 | 1990 | 19 | 0.020 |
Why?
|
| Antibody Specificity | 1 | 1990 | 98 | 0.020 |
Why?
|
| Azathioprine | 1 | 2010 | 16 | 0.020 |
Why?
|
| Virus Activation | 1 | 2010 | 15 | 0.020 |
Why?
|
| Gingival Diseases | 1 | 2010 | 22 | 0.020 |
Why?
|
| Oral Ulcer | 1 | 2010 | 22 | 0.020 |
Why?
|
| Iatrogenic Disease | 1 | 2010 | 36 | 0.020 |
Why?
|
| Immunocompromised Host | 1 | 2010 | 55 | 0.020 |
Why?
|
| Rheumatic Diseases | 1 | 2010 | 35 | 0.020 |
Why?
|
| Stem Cell Transplantation | 1 | 2010 | 58 | 0.020 |
Why?
|
| Hematologic Neoplasms | 1 | 2010 | 37 | 0.020 |
Why?
|
| Immunoblotting | 1 | 1990 | 254 | 0.020 |
Why?
|
| Bleeding Time | 1 | 1990 | 3 | 0.020 |
Why?
|
| Plasminogen | 1 | 1990 | 28 | 0.020 |
Why?
|
| Hot Temperature | 1 | 1990 | 152 | 0.020 |
Why?
|
| Fibrinolysis | 1 | 1990 | 55 | 0.020 |
Why?
|
| Surgical Procedures, Operative | 1 | 1991 | 124 | 0.020 |
Why?
|
| Evaluation Studies as Topic | 1 | 1990 | 219 | 0.020 |
Why?
|
| Chromosomes, Human, Y | 1 | 2009 | 13 | 0.020 |
Why?
|
| Chromosomes, Human, X | 1 | 2009 | 24 | 0.020 |
Why?
|
| Fusion Proteins, bcr-abl | 1 | 2009 | 37 | 0.020 |
Why?
|
| Physical Exertion | 1 | 1990 | 75 | 0.020 |
Why?
|
| Immunity, Maternally-Acquired | 1 | 1989 | 4 | 0.020 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 1 | 2009 | 29 | 0.020 |
Why?
|
| Exchange Transfusion, Whole Blood | 1 | 1989 | 13 | 0.020 |
Why?
|
| Ceramides | 1 | 2013 | 578 | 0.020 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2009 | 63 | 0.020 |
Why?
|
| Gastrointestinal Tract | 1 | 2009 | 62 | 0.020 |
Why?
|
| Neoplasm Transplantation | 1 | 2009 | 160 | 0.020 |
Why?
|
| Muscle, Smooth | 1 | 2009 | 117 | 0.020 |
Why?
|
| Thromboplastin | 1 | 1989 | 21 | 0.020 |
Why?
|
| Mice, Inbred NOD | 1 | 2009 | 138 | 0.020 |
Why?
|
| Platelet Function Tests | 1 | 1989 | 10 | 0.020 |
Why?
|
| Injections, Intravenous | 1 | 1989 | 215 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2018 | 2688 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2011 | 503 | 0.020 |
Why?
|
| Mice, SCID | 1 | 2009 | 238 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2009 | 174 | 0.020 |
Why?
|
| Collagen Type I | 1 | 2009 | 175 | 0.020 |
Why?
|
| Clinical Laboratory Techniques | 1 | 1989 | 60 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 1990 | 546 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2010 | 648 | 0.020 |
Why?
|
| Bioprosthesis | 1 | 2009 | 101 | 0.020 |
Why?
|
| Heart Failure | 1 | 2017 | 1179 | 0.020 |
Why?
|
| Ultrasonography, Doppler, Duplex | 1 | 2008 | 25 | 0.020 |
Why?
|
| Phlebography | 1 | 2008 | 31 | 0.020 |
Why?
|
| Delivery, Obstetric | 1 | 2008 | 58 | 0.020 |
Why?
|
| Erythrocytes, Abnormal | 1 | 1987 | 4 | 0.020 |
Why?
|
| Collagen | 1 | 1991 | 636 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2009 | 710 | 0.020 |
Why?
|
| Eclampsia | 1 | 1987 | 16 | 0.020 |
Why?
|
| Staining and Labeling | 1 | 1988 | 144 | 0.020 |
Why?
|
| Mammaplasty | 1 | 2008 | 41 | 0.020 |
Why?
|
| Aspartate Aminotransferases | 1 | 1987 | 87 | 0.020 |
Why?
|
| Heart Valve Prosthesis | 1 | 2009 | 222 | 0.020 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 1987 | 52 | 0.020 |
Why?
|
| Cesarean Section | 1 | 2008 | 101 | 0.020 |
Why?
|
| Chorionic Villi | 1 | 1987 | 5 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 2008 | 334 | 0.020 |
Why?
|
| Observer Variation | 1 | 2008 | 330 | 0.020 |
Why?
|
| Pneumonia | 1 | 2008 | 110 | 0.020 |
Why?
|
| Mixed Connective Tissue Disease | 1 | 1987 | 9 | 0.020 |
Why?
|
| In Situ Hybridization | 1 | 2007 | 201 | 0.020 |
Why?
|
| Immunosorbent Techniques | 1 | 1986 | 18 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2009 | 453 | 0.020 |
Why?
|
| Patient Selection | 1 | 2011 | 592 | 0.020 |
Why?
|
| Contractile Proteins | 1 | 1986 | 17 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2008 | 567 | 0.020 |
Why?
|
| Immunoelectrophoresis | 1 | 1986 | 16 | 0.020 |
Why?
|
| Immunoelectrophoresis, Two-Dimensional | 1 | 1986 | 2 | 0.020 |
Why?
|
| Vitamin D-Binding Protein | 1 | 1986 | 58 | 0.020 |
Why?
|
| Hospital Mortality | 1 | 2008 | 384 | 0.020 |
Why?
|
| Microfilament Proteins | 1 | 1986 | 102 | 0.020 |
Why?
|
| Factor VIIIa | 1 | 1985 | 1 | 0.020 |
Why?
|
| Arthroplasty, Replacement, Hip | 1 | 2008 | 130 | 0.020 |
Why?
|
| Abdomen | 1 | 1986 | 80 | 0.020 |
Why?
|
| Eye Proteins | 1 | 1987 | 160 | 0.020 |
Why?
|
| Receptors, Antigen, B-Cell | 1 | 1986 | 89 | 0.020 |
Why?
|
| Postoperative Period | 1 | 1986 | 238 | 0.020 |
Why?
|
| Vincristine | 1 | 2005 | 44 | 0.020 |
Why?
|
| Age Factors | 1 | 1990 | 1860 | 0.020 |
Why?
|
| Immunoassay | 1 | 1985 | 64 | 0.020 |
Why?
|
| Recurrence | 1 | 1987 | 948 | 0.020 |
Why?
|
| Chemistry, Physical | 1 | 1984 | 21 | 0.020 |
Why?
|
| Chemical Phenomena | 1 | 1984 | 62 | 0.020 |
Why?
|
| Ceftriaxone | 1 | 2004 | 32 | 0.020 |
Why?
|
| Cyclophosphamide | 1 | 2005 | 129 | 0.020 |
Why?
|
| Phospholipids | 1 | 1985 | 108 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2011 | 2004 | 0.020 |
Why?
|
| Autoimmune Diseases | 1 | 1986 | 186 | 0.020 |
Why?
|
| Blood Vessels | 1 | 1984 | 102 | 0.020 |
Why?
|
| Drug Interactions | 1 | 1985 | 289 | 0.020 |
Why?
|
| South Carolina | 1 | 2011 | 2750 | 0.020 |
Why?
|
| Body Weight | 1 | 1986 | 554 | 0.010 |
Why?
|
| Umbilical Veins | 1 | 1983 | 54 | 0.010 |
Why?
|
| Doxorubicin | 1 | 2005 | 231 | 0.010 |
Why?
|
| Transplantation, Autologous | 1 | 2003 | 145 | 0.010 |
Why?
|
| Lymph Node Excision | 1 | 2003 | 91 | 0.010 |
Why?
|
| Thrombin Time | 1 | 1983 | 1 | 0.010 |
Why?
|
| Proteins | 1 | 1986 | 473 | 0.010 |
Why?
|
| Anastomosis, Surgical | 1 | 2002 | 104 | 0.010 |
Why?
|
| Lymph Nodes | 1 | 2003 | 258 | 0.010 |
Why?
|
| Radioimmunoassay | 2 | 1979 | 164 | 0.010 |
Why?
|
| Glucose | 1 | 1983 | 307 | 0.010 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 1990 | 1085 | 0.010 |
Why?
|
| Mesenteric Veins | 1 | 1999 | 10 | 0.010 |
Why?
|
| Blood Pressure | 1 | 1986 | 1447 | 0.010 |
Why?
|
| Sigmoidoscopy | 1 | 1999 | 38 | 0.010 |
Why?
|
| Rabbits | 2 | 1993 | 509 | 0.010 |
Why?
|
| Gestational Age | 2 | 1993 | 389 | 0.010 |
Why?
|
| Colon | 1 | 1999 | 168 | 0.010 |
Why?
|
| Prenatal Diagnosis | 1 | 1979 | 73 | 0.010 |
Why?
|
| Epitope Mapping | 1 | 1998 | 10 | 0.010 |
Why?
|
| Cross Reactions | 1 | 1998 | 57 | 0.010 |
Why?
|
| Epitopes | 1 | 1978 | 146 | 0.010 |
Why?
|
| Heart Defects, Congenital | 1 | 2002 | 596 | 0.010 |
Why?
|
| Cattle | 1 | 1998 | 475 | 0.010 |
Why?
|
| Anemia, Macrocytic | 1 | 1996 | 4 | 0.010 |
Why?
|
| Fetal Hemoglobin | 1 | 1996 | 10 | 0.010 |
Why?
|
| Proteinuria | 1 | 1996 | 136 | 0.010 |
Why?
|
| Creatinine | 1 | 1996 | 243 | 0.010 |
Why?
|
| Endothelium | 2 | 1984 | 98 | 0.010 |
Why?
|
| Bacteroides | 1 | 1973 | 7 | 0.010 |
Why?
|
| Streptococcus | 1 | 1973 | 15 | 0.010 |
Why?
|
| Clostridium | 1 | 1973 | 10 | 0.010 |
Why?
|
| Infusions, Parenteral | 1 | 1993 | 47 | 0.010 |
Why?
|
| Pleura | 1 | 1993 | 25 | 0.010 |
Why?
|
| Enterobacteriaceae | 1 | 1973 | 29 | 0.010 |
Why?
|
| Staphylococcus | 1 | 1973 | 29 | 0.010 |
Why?
|
| Tissue Adhesions | 1 | 1993 | 21 | 0.010 |
Why?
|
| Radionuclide Imaging | 1 | 1973 | 166 | 0.010 |
Why?
|
| Biliary Tract Diseases | 1 | 1973 | 50 | 0.010 |
Why?
|
| Macromolecular Substances | 1 | 1993 | 122 | 0.010 |
Why?
|
| Plasma | 1 | 1992 | 58 | 0.010 |
Why?
|
| Filtration | 1 | 1992 | 61 | 0.010 |
Why?
|
| Glucose Tolerance Test | 1 | 1990 | 75 | 0.010 |
Why?
|
| Microchemistry | 1 | 1987 | 19 | 0.000 |
Why?
|
| Fluoresceins | 1 | 1987 | 31 | 0.000 |
Why?
|
| Fluorescein | 1 | 1987 | 15 | 0.000 |
Why?
|
| Histocytochemistry | 1 | 1987 | 149 | 0.000 |
Why?
|
| Tissue Plasminogen Activator | 1 | 1990 | 296 | 0.000 |
Why?
|
| Profilins | 1 | 1986 | 1 | 0.000 |
Why?
|
| Arrestin | 1 | 1987 | 12 | 0.000 |
Why?
|
| Ultrafiltration | 1 | 1986 | 35 | 0.000 |
Why?
|
| Muscles | 1 | 1986 | 158 | 0.000 |
Why?
|
| Connective Tissue Diseases | 1 | 1986 | 18 | 0.000 |
Why?
|
| Kinetics | 1 | 1986 | 1047 | 0.000 |
Why?
|
| Fetoscopy | 1 | 1979 | 4 | 0.000 |
Why?
|
| Pregnancy Trimester, Second | 1 | 1979 | 58 | 0.000 |
Why?
|
| Amniotic Fluid | 1 | 1979 | 30 | 0.000 |
Why?
|
| Risk | 1 | 1979 | 563 | 0.000 |
Why?
|